Physician profile

Daniel S Sieger

Anesthesiology · Delray Beach, FL

NPI 1114031358

$460.60

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$262.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $124.22 2024
Chiesi USA, INC. $84.39 2020-2023 Cleviprex
Edwards Lifesciences Corporation $60.19 2022
Pacira Pharmaceuticals Incorporated $43.43 2020-2024 Zilretta, Iovera, Exparel
Csl Behring $42.00 2021-2023 Kcentra
Merck Sharp & Dohme LLC $34.94 2019-2023 Bridion
Cumberland Pharmaceuticals, INC. $33.43 2020-2023 Caldolor
Glaukos Corporation $19.09 2024 Idose
Lilly USA, LLC $18.91 2024 Omvoh

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel S Sieger

$460.60

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbvie INC.

https://glasscript.com/doctor/907124/daniel-s-sieger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.